25 Apr FDA extends use of Tagrisso to metastatic non-small-cell lung cancer
AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epidermal growth factor receptor (EGFR) mutations.
Tagrisso is already approved in the US as a second-line treatment for this subgroup of lung cancer patients, whose disease progressed on or after a first-line EGFR-TKI therapy and who have developed the secondary T790M mutation. In trials Tagrisso (osimertinib) significantly improved progression-free survival (PFS) compared to current treatment (18.9 months compared to 10.2 months for those receiving the standard of care). Positive response to Tagrisso was 80% compared to 76% of the current treatment.
Tagrisso is now under regulatory review in the European Union and Japan for use in the first-line treatment setting with regulatory decisions anticipated in the second half of 2018.
* * *
FarmaMondo is a Swiss-based pharmaceutical service provider specialized in ethical and responsible access to medicines. We deliver specialty pharma products and orphan drugs to satisfy unmet medical needs worldwide.
For more information about FarmaMondo and news related to Pharma Market please contact us at email@example.com
LEGAL DISCLAIMER. All the information on this website is published in good faith and for general information purpose only. does not make any warranties about the completeness reliability and accuracy of this information. Any action you take upon the information you find on this website is strictly at your own risk.
FarmaMondo Sa will not be liable for any losses and/or damages in connection with the use of its website.